NASDAQ:RVPH Reviva Pharmaceuticals Q1 2025 Earnings Report $0.55 -0.04 (-7.08%) As of 07/14/2026 03:51 PM Eastern ProfileEarnings HistoryForecast Reviva Pharmaceuticals EPS ResultsActual EPS-$2.60Consensus EPS -$4.20Beat/MissBeat by +$1.60One Year Ago EPSN/AReviva Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AReviva Pharmaceuticals Announcement DetailsQuarterQ1 2025Date5/15/2025TimeBefore Market OpensConference Call DateThursday, May 15, 2025Conference Call Time4:00PM ETUpcoming EarningsReviva Pharmaceuticals' Q2 2026 earnings is estimated for Thursday, August 13, 2026, based on past reporting schedules, with a conference call scheduled on Monday, August 17, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Reviva Pharmaceuticals Earnings HeadlinesReviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Average Recommendation of "Moderate Buy" by Analysts2 hours ago | americanbankingnews.comReviva Pharmaceuticals (NASDAQ:RVPH) Stock Rating Upgraded by Wall Street ZenJuly 5, 2026 | americanbankingnews.comRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change. | Porter & Company (Ad)Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24thJune 23, 2026 | financialpost.comFReviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24thJune 23, 2026 | globenewswire.comReviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company ShowcaseMay 18, 2026 | finance.yahoo.comSee More Reviva Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Reviva Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Reviva Pharmaceuticals and other key companies, straight to your email. Email Address About Reviva PharmaceuticalsReviva Pharmaceuticals (NASDAQ:RVPH), Inc. (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes. The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings. Reviva maintains a lean operating model, leveraging partnerships with contract development and manufacturing organizations (CDMOs) to accelerate product development and optimize market entry. Reviva’s current offerings span oral, injectable and topical dosage forms across therapeutic areas including metabolic disorders, dermatology and ophthalmology. In addition to its marketed portfolio, the company is advancing reformulation projects designed to improve delivery profiles, simplify dosing regimens and extend product lifecycles for previously approved drugs. Led by Chief Executive Officer Mark C. Capparelli, Reviva’s management team combines expertise in pharmaceutical development, regulatory strategy and commercialization. The company serves markets throughout North America and works with specialty distributors in select regions to ensure broad patient access to its branded and licensed products.View Reviva Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity YetJPMorgan’s Q2 Strength Gives the Stock Rally New SupportPrepare for the Next Wave of Factory Automation With These 3 Standout NamesAnalysts See Major Upside for These 5 StocksMarketBeat Week in Review – 07/06 - 07/10Delta Air Lines Lives Up to Its Claims: Shares Can Keep ClimbingWhy WD-40 Is Proving Great Businesses Never Go Out of Style Upcoming Earnings GE Aerospace (7/16/2026)Taiwan Semiconductor Manufacturing (7/16/2026)Netflix (7/16/2026)Prologis (7/16/2026)U.S. Bancorp (7/16/2026)Abbott Laboratories (7/16/2026)Intuitive Surgical (7/16/2026)UnitedHealth Group (7/16/2026)Fifth Third Bancorp (7/17/2026)Truist Financial (7/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
